Clinical stage biotechnology company SynAct Pharma AB (STO:SYNACT) announced on Wednesday that it has received a Notice of Allowance from the United States Patent and Trademark Office for patent application US 17/609,849.

The patent covers the use of resomelagon (AP1189) in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis, aligning with SynAct's lead clinical programme where resomelagon is used as an add-on to first-line MTX therapy.

Once granted, the new patent will be enforceable until at least 2040, strengthening SynAct's intellectual property portfolio in the US market.

This development supports SynAct's strategic aim of securing exclusivity for its combination treatment approach in key global markets.

The new allowance complements previously granted US patent US 12,239,63, which covers the crystal form of the resomelagon salt used in clinical settings.

SynAct continues to actively pursue patent protection for resomelagon across multiple jurisdictions worldwide.

The Notice of Allowance indicates that a formal US patent will be issued once all administrative requirements are fulfilled.